Silvia Ferrari

机构：Baxter (Austria), Ospedale Papa Giovanni XXIII · ORCID：0000-0002-9917-2843

发表论文 137 篇 · 总被引 2117 次 · h-index 22

代表论文

• Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study (2024 · Leukemia · 被引 34)
• Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation (2025 · Blood Cancer Journal · 被引 14)
• Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi (2023 · HemaSphere · 被引 13)
• Real-world collection of secondary myeloid neoplasms after CD19 CAR-T cell therapy: first report of the ClonHema study (2025 · Bone Marrow Transplantation · 被引 9)
• Acquisition of an immunosuppressive microenvironment after anti-CD19 CAR T-cell therapy is associated with T-cell dysfunction and resistance (2025 · Journal for ImmunoTherapy of Cancer · 被引 8)
• ABCL-777: Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) (2025 · Clinical Lymphoma Myeloma & Leukemia · 被引 8)